<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03703817</url>
  </required_header>
  <id_info>
    <org_study_id>A3921304</org_study_id>
    <secondary_id>RA SATISFACTION</secondary_id>
    <nct_id>NCT03703817</nct_id>
  </id_info>
  <brief_title>Rheumatoid Arthritis Satisfaction Outcome Research</brief_title>
  <official_title>TREATMENT SATISFACTION COMPARISON IN RHEUMATOID ARTHRITIS PATIENTS BETWEEN TOFACITINIB CITRATE AND ADALIMUMAB, EACH USED IN RHEUMATOID ARTHRITIS TREATMENT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Program in Biostatistics, College of Medicine, Korea University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The way communications</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      RA satisfaction OR: This study aim to compare treatment satisfaction and quality of life
      between patients who have been using tofacitinib citrate and patients who have been using
      adalimumab for 6 months or more and less than 2 year in RA treatment of rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RA satisfaction OR: This study aim to compare treatment satisfaction and quality of life
      between patients who have been using tofacitinib citrate and patients who have been using
      adalimumab for 6 months or more and less than 2 year in RA treatment of rheumatoid arthritis.

      Study design: Non-interventional, multi-centers, cross-sectional study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2018</start_date>
  <completion_date type="Actual">March 12, 2020</completion_date>
  <primary_completion_date type="Actual">March 12, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Satisfaction Questionnaire for Medication for treatment satisfaction</measure>
    <time_frame>Baseline</time_frame>
    <description>Participant's response to treatment satisfaction will be collected using Treatment Satisfaction Questionnaire for Medication version 1.4. TSQM has 4 domains of Effectiveness, Convenience, Global satisfaction and Side effects. And there are 14 questions in total. The range of scores by each domain is from 0 to 100 where higher scores indicate great treatment satisfaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EuroQoL-5 dimension-3 level index for Quality of life</measure>
    <time_frame>Baseline</time_frame>
    <description>Participant's response to Quality of Life will be collected using EuroQoL-5 dimension-3 level index. EQ-5D-3L has 5 questions that thdy are asked to check on 3 point scale as 'no problems', 'some problems' and 'extreme problems'. Using scores of questions, the EQ-5D score will be calculated Through a fomula. The range of score is from -0.229 to 1.00 where higher scores indicate good quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQoL Visual Analogue Scale for health status</measure>
    <time_frame>Baseline</time_frame>
    <description>The EQ VAS requires patients to mark their health status on a visual analog scale. Patients will mark VAS of both current status and death. The range of scores by each domain is from 0 to 100 where higher scores indicate good status. Using VAS scores, the EQ-VAS score will be calculated Through a fomula. The range of score is from -1 to 1 where higher scores indicate good quality of life.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">413</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>tofacitinib citrate users</arm_group_label>
    <description>patients who have been using tofacitinib citrate for 6 months or more and less than 2 year in RA patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adalimumab users</arm_group_label>
    <description>patients who have been using adalimumab for 6 months or more and less than 2 year in RA patients</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is RA patients who have been using tofacitinib citrate or adalimumab
        for 6 months or more and less than 2 year in RA treatment at participating institution
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged 19 years or older

          2. Patients diagnosed with RA

          3. Treatment groups:

        1) Tofacitinib citrate users: Patients currently on treatment with tofacitinib citrate in
        RA therapy for 6 months or more 2) Adalimumab users: Patients currently on treatment with
        adalimumab in the RA therapy for 6 months or more 4. Reading and writing with enough
        proficiency to complete assessment instruments in Korean

        Exclusion Criteria:

          1. Patients currently on tofacitinib citrate or adalimumab for 2 year or more

          2. Patients taking Azathioprine and cyclosporine

          3. Patients participating in other drug interventional study

          4. Patients who have been treated with bDMARDs except Rheumatoid arthritis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyung Hee University Hospital at Gangdong / Rheumatology</name>
      <address>
        <city>Seoul</city>
        <state>Gangdong-gu</state>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonkwang University Hospital / Division of Rheumatology</name>
      <address>
        <city>Iksan</city>
        <state>Jeonlabuk-do</state>
        <zip>570711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital, Department of Rheumatology</name>
      <address>
        <city>Suwon-si</city>
        <state>Kyeongki-do</state>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji University Hospital</name>
      <address>
        <city>Daejeon</city>
        <state>Republic OF Korea</state>
        <zip>35233</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Songpa-gu</city>
        <state>Seoul</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital/Rheumatology, Internal Medicine</name>
      <address>
        <city>Anyang</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital, Department of Internal Medicine</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <zip>6</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center, Department of Rheumatology</name>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gacheon Medical School Gil Medical Center, Rheumatology, Internal Medicine</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Hospital, Department of Rheumatology</name>
      <address>
        <city>Seoul</city>
        <zip>133-792</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Korea, Kangnam St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Hospital, Department of Rheumatology</name>
      <address>
        <city>Seoul</city>
        <zip>143-914</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>158-056</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=A3921304</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2018</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

